Properties of poly(lactic-co-glycolic acid) nanospheres containing protease inhibitors: Camostat mesilate and nafamostat mesilate

International Journal of Pharmaceutics

Volumn 314, Issue 1, 2006, Pages 46-55

  Yin, Jiahui ^a   Noda, Yasuhiro ^a   Yotsuyanagi, Toshihisa ^b  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b AICHI GAKUIN UNIVERSITY   (Japan)

Author keywords

Camostat mesilate; Emulsion solvent diffusion in oil method; In vitro release; Nafamostat mesilate; Nanospheres; Poly(lactic co glycolic acid)

Indexed keywords

CAMOSTAT MESILATE; NAFAMSTAT MESILATE; NANOPARTICLE; OIL; POLYASPARTIC ACID; POLYGLACTIN; POLYMER; PROTEINASE INHIBITOR; WATER;

ARTICLE; ATOMIC FORCE MICROSCOPY; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION; DISPERSION; DRUG RELEASE; EMULSION; ENCAPSULATION; EVAPORATION; GLASS TRANSITION TEMPERATURE; MOLECULAR WEIGHT; MORPHOLOGY; PRIORITY JOURNAL; TEMPERATURE DEPENDENCE;

CHEMISTRY, PHARMACEUTICAL; GABEXATE; GUANIDINES; LACTIC ACID; MOLECULAR WEIGHT; NANOTUBES; PARTICLE SIZE; PEPTIDES; POLYGLYCOLIC ACID; POLYMERS; PROTEASE INHIBITORS; SOLUBILITY;

EID: 33646087189     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2006.01.047     Document Type: Article

References (29)

1. Akizawa T., Koshikawa S., Iwamoto S., Azetori M., and Komatsu S. Pharmacokinetic studies of regional anticoagulant-FUT-175 in hemodialysis. Jin to Toseki 26 (1989) 947-953 (in Japanese)
2. Avgoustakis K., Beletsi A., Panagi Z., Klepetsanis P., Karydas A.G., and Ithakissios D.D. PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J. Contr. Rel. 79 (2002) 123-135
3. In: Fan L.T., and Singh S.K. (Eds). Controlled Release: A Quantitative Treatment (1989), Springer-Verlag, Berlin 20-28
4. Gaspar M.M., Blanco D., Cruz M.E.M., and Alonso M.J. Formulation of l-asparaginase-loaded poly(lactide-co-glycolide) nanoparticles: influence of polymer properties on enzyme loading, activity and in vitro release. J. Contr. Rel. 52 (1998) 53-62
5. Govender T., Riley T., Ehtezazi T., Garnett M.C., Stolnik S., Illum L., and Davis S. Defining the drug incorporation properties of PLA-PEG nanoparticles. Int. J. Pharm. 199 (2000) 95-110
6. Graves R.A., Pamujula S., Moiseyev R., Freeman T., Bostanin L.A., and Mandal T.A. Effect of different ratios of high and low molecular weight PLGA blend on the characteristics of pentamidine microcapsules. Int. J. Pharm. 270 (2004) 251-262
7. Higuchi W.I. The analysis of data on the medicament release from ointments. J. Pharm. Sci. 51 (1962) 802-804
8. Hiraku S., Muryobayashi K., Ito H., Inagawa T., and Tsuboshima M. Absorption and excretion of camostat (FOY-305) orally administered to male rabbit and healthy subject. Iyakuhin Kenkyu 13 (1982) 756-765 (in Japanese)
9. Hiwasa T., Kondo K., Nakagawara A., and Ohkoshi M. Potent growth-suppressive activity of a serine protease inhibitor, ONO-3403, toward malignant human neuroblastoma cell lines. Cancer Lett. 126 (1998) 221-225
10. Horisawa E., Hirota T., Kawazoe S., Yamada J., Yamamoto H., Takeuchi H., and Kawashima Y. Prolonged anti-inflammatory action of dl-lactide/glycolide copolymer nanospheres containing betamethasone sodium phosphate for an intra-articular delivery system in antigen-induced arthritic rabbit. Pharm. Res. 19 (2002) 403-410
11. Jain R.A. The manufacturing techniques of various drug loaded biodegrable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21 (2000) 2475-2490
12. Jalil R., and Nixon J.R. Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: problems associated with preparative techniques and release properties. J. Microencapsulation 7 (1990) 297-325
13. Kawashima Y., Yamamoto H., Takeuchi H., Hino T., and Niwa T. Properties of a peptide containing dl-lactide/glycolide copolymer nanospheres prepared by novel emulsion solvent diffusion methods. Eur. J. Pharm. Biopharm. 45 (1998) 41-48
14. Kawashima Y., Yamamoto H., Takeuchi H., and Kuno Y. Mucoadhesive dl-lactide/glycolide copolymer nanospheres coated with chitosan to improve oral delivery of elcatonin. Pharm. Dev. Tech. 5 (2000) 77-85
15. Muramatsu M., and Fuji S. Inhibitory effects of ω-guanidino acid esters on trypsin, plasmin, plasma kallikrein and thrombin. Biochim. Biophys. Acta 268 (1972) 221-224
16. Nakahara M. Inhibitory effect of aprotinin and gabexate mesilate of human plasma kallikrein. Arzneim. Forsch./Drug Res. 33 (1983) 969-971
17. Nishijima M.K., Takezawa J., Taenaka N., Shimada Y., and Yoshiya I. Application of HPLC measurement of plasma concentration of gabaxate mesilate. Thromb. Res. 31 (1983) 279-284
18. Nishiyama N., Kato Y., Sugiyama Y., and Kataoka K. Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system. Pharm. Res. 18 (2001) 1035-1041
19. Niwa T., Takeuchi H., Hino T., Kunou N., and Kawashima Y. Preparations of biodegradable nanospheres of water-soluble and insoluble drugs with d,l-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. J. Contr. Rel. 25 (1993) 89-98
20. Niwa T., Takeuchi H., Hino T., Kunou N., and Kawashima Y. In vitro drug release behavior of d,l-lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate prepared by a novel spontaneous emulsification solvent diffusion method. J. Pharm. Sci. 83 (1994) 727-732
21. Ogawa Y., Okada H., Heya T., and Shimamoto T. Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: serum drug level profiles and pharmacological effects in animals. J. Pharm. Pharmacol. 41 (1989) 439-444
22. Ohkoshi M. Protease inhibitor and cancer therapy. Gann To Kagaku Ryoho 22 (1995) 417-429 (in Japanese)
23. Ohta N., Yotsuyanagi T., and Ikeda K. Degradation of gabexate mesilate catalyzed by human serum albumin. Int. J. Pharm. 29 (1986) 137-146
24. Okada H. One and three-month release injectable microspheres of LH-RH superagonist leuprorelin acetate. Adv. Drug Deliv. Rev. 28 (1997) 43-70
25. Park T.G. Degradation of poly(d,l-lactic acid) microspheres: effect of molecular weight. J. Contr. Rel. 30 (1994) 161-173
26. Shibuya M., Komatsu S., Honma R., and Katsuhata A. Studies on Serum protein binding of FUT-175. Kiso To Rinnsho 18 (1984) 5725-5731 (in Japanese)
27. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., and Rudzinski W.E. Biodegradable polymeric nanoparticles as drug devices. J. Contr. Rel. 70 (2001) 1-20
28. In: Takaku F., and Yazaki Y. (Eds). Protease Inhibitors, Manual of Therapeutic Agents (2005), Igaku Shoin, Tokyo 711-712
29. Yokoyama M., Miyauchi M., Yamada N., Okano T., Sakurai Y., Kataoka K., and Inoue S. Characterization and anticancer activity of the micelle-forming polymeric anticancer adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. Cancer Res. 50 (1990) 1693-1700